Spero Therapeutics
SPRO
46 hedge funds and large institutions have $16.5M invested in Spero Therapeutics in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 7 closing their positions.
2.87% less ownership
Funds ownership: 25.7% → 22.84% (-2.9%)
4% less funds holding
Funds holding: 48 → 46 (-2)
8% less capital invested
Capital invested by funds: $18M → $16.5M (-$1.5M)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$28.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$23.1K |
| 3 |
TSW
Three Seasons Wealth
Salt Lake City,
Utah
|
+$20.1K |
| 4 |
PI
PFG Investments
Woodbury,
New York
|
+$18.8K |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$13.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$1.14M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$309K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$235K |
| 4 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$178K |
| 5 |
Millennium Management
New York
|
-$89K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AF
51
Allworth Financial
Folsom,
California
| – | -$840 | -600 | Closed |
|
52
RhumbLine Advisers
Boston,
Massachusetts
| – | -$595 | -458 | Closed |
|
53
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$1 | -1 | Closed |
|
SPRO Hedge Fund Activity: Q3 2024 in Review
46 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q3 2024, worth a combined $16.5M — down 8.3% from $18M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SPRO and 5 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 6 added.
The largest buyer was Susquehanna International Group, adding an estimated $28.4K. The largest seller was Murchinson, exiting entirely with an estimated $1.14M sold.
- 46 institutional investors held Spero Therapeutics (SPRO) as of Q3 2024, down from 48 in Q2 2024.
- Funds reported $16.5M of Spero Therapeutics stock for Q3 2024, down 8.3% quarter-over-quarter.
- 5 funds opened new Spero Therapeutics positions in Q3 2024 and 7 closed out, a net change of -2 holders.
- The largest Spero Therapeutics buyer in Q3 2024 was Susquehanna International Group, an estimated $28.4K added.
- The largest Spero Therapeutics seller in Q3 2024 was Murchinson, an estimated $1.14M sold.
Based on aggregated 13F filings for Q3 2024.